The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.
 
Miguel Angel Villalona-Calero
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - Lilly
Speakers' Bureau - Amgen
Research Funding - Amgen - Local PI (Inst); cyclacel local PI (Inst); Hummingbird local PI (Inst); IDEAYA local PI (Inst); Kronos- local PI (Inst); Zenshine local PI (Inst)
 
Glenn J. Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)
 
Mark Agulnik
Consulting or Advisory Role - AADi; Boehringer Ingelheim
Speakers' Bureau - Deciphera
Research Funding - Exelixis (Inst)
 
Monica M. Mita
No Relationships to Disclose
 
Alain C. Mita
Speakers' Bureau - Genentech
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Evelo Biosciences (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Jia Luo
Honoraria - Physicans' Education Resource; Targeted Oncology; VJOncology
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca
Research Funding - Erasca, Inc; Genentech; Kronos Bio; Novartis; Revolution Medicines
Travel, Accommodations, Expenses - Blueprint Medicines; Daiichi Sankyo; Erasca, Inc
 
Gregory Michael Cote
Honoraria - BioAtla; Gilead Sciences
Consulting or Advisory Role - C4 Therapeutics; Daiichi Sankyo/UCB Japan; Ikena Oncology; Sonata
Research Funding - Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Pyxis (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Jyoti Malhotra
Consulting or Advisory Role - Abbvie; AstraZeneca; BioAtla; Bristol Myers Squibb Foundation; Catalyst Pharmaceuticals; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; Mirati Therapeutics; OncoCyte; Regeneron; Sanofi; Takeda
Speakers' Bureau - Tempus
Research Funding - BeyondSpring Pharmaceuticals (Inst); Biohaven Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst)
 
Mohamad Adham Salkeni
Employment - Next Oncology; Virginia Cancer Specialists
Stock and Other Ownership Interests - Next Oncology
Honoraria - Healthcasts
Research Funding - 1ST Biotherapeutics (Inst); Agenus (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); CrystalGenomics (Inst); IDEAYA Biosciences (Inst); Inmune Bio (Inst); Kronos Bio (Inst); MBrace Therapeutics (Inst); OncoResponse (Inst); Oncternal Therapeutics (Inst); Prelude Therapeutics (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Tarus Therapeutics (Inst)
 
Natraj Reddy Ammakkanavar
Stock and Other Ownership Interests - Autolus; Cardiff Oncology; Iovance Biotherapeutics; Kura Oncology; Shockwave Medical
Consulting or Advisory Role - AstraZeneca/MedImmune
Speakers' Bureau - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Loxo/Lilly
 
Amol Rao
Employment - Memorial Care
Research Funding - Kronos Bio (Inst)
 
Kamalesh Sankhala
Employment - NextGen Oncology
Research Funding - Kronos Bio (Inst)
 
Richard E. Cutler
Employment - Kronos Bio
Stock and Other Ownership Interests - Kronos Bio
Travel, Accommodations, Expenses - Kronos Bio
 
Tressa Hood
Employment - Kronos Bio
Stock and Other Ownership Interests - Kronos Bio
Travel, Accommodations, Expenses - Kronos Bio
 
Luis A. Carvajal
Employment - Kronos Bio
Stock and Other Ownership Interests - Kronos Bio
Travel, Accommodations, Expenses - Kronos Bio
 
Charles Lin
Employment - Kronos Bio
Leadership - Kronos Bio
Stock and Other Ownership Interests - Amgen; Kronos Bio
Consulting or Advisory Role - 76Bio; Cambridge Science Corporation
Patents, Royalties, Other Intellectual Property - IP licensed to Syros Pharmaceuticals; software licensed by Baylor College of Medicine
 
Jorge F. DiMartino
Employment - Kronos Bio
Leadership - Kronos Bio
Stock and Other Ownership Interests - BMS; Kronos Bio
Travel, Accommodations, Expenses - Kronos Bio
 
Elizabeth Olek
Employment - Kronos Bio
Stock and Other Ownership Interests - Kronos Bio; Loxo
Travel, Accommodations, Expenses - Kronos Bio; Loxo
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc